These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22050392)

  • 1. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
    Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
    J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
    Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
    J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
    Gilligan AM; Gandhi P; Song X; Wang C; Henriques C; Sander S; Smith DM
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):481-492. PubMed ID: 28795348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
    Song X; Gandhi P; Gilligan AM; Arora P; Wang C; Henriques C; Sander S; Smith DM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):213-222. PubMed ID: 28649894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.
    Vestergaard AS; Skjøth F; Lip GY; Larsen TB
    Stroke; 2016 Apr; 47(4):979-85. PubMed ID: 26883499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
    Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):203-212. PubMed ID: 30251553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
    Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
    Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants.
    Fermann GJ; Lovelace B; Christoph MJ; Lingohr-Smith M; Lin J; Deitelzweig SB
    J Med Econ; 2020 Dec; 23(12):1409-1417. PubMed ID: 33054507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA.
    Deitelzweig SB; Lovelace B; Christoph M; Lingohr-Smith M; Lin J; Fermann GJ
    Adv Ther; 2020 Sep; 37(9):3942-3953. PubMed ID: 32699994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.
    Suh DC; Nelson WW; Choi JC; Choi I
    Clin Ther; 2012 Jul; 34(7):1569-82. PubMed ID: 22717419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
    Deitelzweig S; Neuman WR; Lingohr-Smith M; Menges B; Lin J
    J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation.
    Abdelhafiz AH; Wheeldon NM
    Am J Geriatr Pharmacother; 2003 Dec; 1(2):53-60. PubMed ID: 15555467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
    Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
    J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.